Bill Lundberg Departs CRISPR Therapeutics as CSO
Bill Lundberg has stepped down as CSO of CRISPR Therapeutics. In his absence, Tony Ho, M.D., will oversee CRISPR’s R&D activities.
The company made the news public the same day as Celgene disclosed it has sold more of the biotech’s stock, writes Fierce Biotech.
Speaking of his departure, Lundberg said, “I have had the privilege of working with a wonderful, talented and dedicated group of people at CRISPR Therapeutics. We have filed the first company-sponsored clinical trial applications for CRISPR-based therapies and is now a natural time for me to transition to a Senior Advisor role. I am confident in the success of the CRISPR team to continue to advance important gene-based medicines for patients suffering from devastating diseases.”
Samarth Kulkarni, CEO, added, “Bill was instrumental in establishing our research operations and advancing our CRISPR/Cas9 platform from the research phase to clinical evaluation. On behalf of CRISPR Therapeutics, I thank Bill for his leadership and look forward to his continued involvement.”
Lundberg began his career in 2015 with a brief to lead the establishment of its R&D operation. His departure is immediate but the ex-Alexion VP will continue to help CRISPR as a senior advisor and as head of its scientific advisory board.
As it stands, Celgene’s stake in the organisation now stands at 6.1%, less than half what it was 16 months ago. However, Bayer has played slightly differently, and continued to add to its stake in the biotech.